TikTok Moment For BeiGene, Junshi As FDA Looks At China PD-1s
At Least One To Score Approval?
Executive Summary
Amid deepening bilateral decoupling and geopolitical tensions, the US regulatory agency is sending field inspectors to China for the first time in three years as it moves forward in reviewing and potentially approving the first 'Made In China' immuno-oncology drugs.
You may also be interested in...
China-US Health Regulatory Dialogue In Crosshairs Amid Biden-Xi Summit
Beijing’s application to join an international pharma inspections scheme offers a rare opportunity to revitalize a largely downsized US-China dialogue, but domestic pressure and public opinion may jeopardize the opportunity.
Transforming Coherus Adds To IO Pipeline Via Merger With Surface Oncology
Currently battling AbbVie over pricing plans for its Humira biosimilar, Coherus is also looking to become an immuno-oncology player, acquiring two more clinical assets in an all-stock deal.
Transforming Coherus Adds To IO Pipeline Via Merger With Surface Oncology
Currently battling AbbVie over pricing plans for its Humira biosimilar, Coherus is also looking to become an immuno-oncology player, acquiring two more clinical assets in an all-stock deal.